BioCentury
ARTICLE | Distillery Therapeutics

Therapeutics: Phosphoinositide 3-kinase class 2 subunit β polypeptide (PI3KC2B); myotubularin 1 (MTM1); phosphatidylinositol-3-phosphate (PI3P)

September 22, 2016 7:00 AM UTC

Mouse and zebrafish studies suggest inhibiting PI3KC2B could help treat myotubular myopathy, which is caused by mutations in MTM1. In a mouse model of the disease, muscle-specific knockout of PI3KC2B ...